A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Starting soon · Phase 2/Phase 3

Conditions studied: Hepatocellular Carcinoma (HCC)

In brief

To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma

Key facts

Study ID
NCT07392866
Run by
Nanjing Sanhome Pharmaceutical, Co., Ltd.
People needed
120
Starts
2026-03-01
Expected to finish
2030-03-01
Last updated by the study team
2026-02-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.